Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A

4.02
HKD
0.00
(0.00%)
0.10EPS
37.93P/E
15.85BMarket Cap
Apr 01Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.44
0.57
0.68
0.68
0.86
1.45
1.39
1.48
1.63
1.83
1.39
1.35
1.4
2.45
Basic EPS, GAAP
0.09
0.1
0.17
0.12
0.06
0.18
0.32
0.28
0.06
0.19
-0.2
0.17
0.09
0.09
Free Cash Flow per Basic Share
0.04
0.22
0.21
- -
-0.35
0.03
-0.18
-0.05
-0.05
-0.25
-0.01
0.51
0.41
- -
Dividend per Share
0.14
0.08
0.09
0.16
0.14
0.08
0.1
0.12
0.11
0.06
0.11
0.04
0.11
0.12
Book Value per Share
2.34
2.43
2.56
2.4
2.34
1.84
2.21
2.96
2.92
3.15
3.05
3.11
3.08
3.08
Tangible Book Value per Share
2.29
1.99
1.71
1.48
1.45
0.91
1.3
2.24
2.22
2.4
2.33
2.4
2.41
2.45
Basic Weighted Avg Shares
3,410
3,410
3,376
3,340
3,321
3,322
3,322
3,604
3,908
3,910
3,908
3,908
3,908
2,078
Sales/Revenue/Turnover
1,513
1,959
2,292
2,261
2,843
4,815
4,625
5,332
6,365
7,159
5,446
5,281
5,479
5,081
Operating Margin (%)
10.01
12.31
19.63
11.78
10.36
22.47
17.93
21.13
15.15
15.68
11.75
14.06
11.61
11.59
Depreciation Expense
25
39
98
162
183
223
256
304
303
308
374
331
373
- -
Net Income, GAAP
317
338
580
397
197
591
1,059
1,024
241
727
-783
647
349
190
Effective Tax Rate (%)
17.3
15.45
17.73
18.7
- -
19.08
20.64
23.06
- -
13.84
- -
13.95
14.82
- -
Profit Margin (%)
20.97
17.27
25.29
17.55
6.92
12.28
22.91
19.21
3.78
10.16
-14.38
12.25
6.38
3.74
Working Capital
7,046
6,572
5,561
4,637
2,254
938
1,003
5,516
5,978
6,814
5,618
5,922
5,198
5,637
LT Debt
- -
1,005
1,785
2,095
1,824
2,449
2,442
3,137
2,354
2,407
1,900
1,139
338
59
Total Equity
8,068
8,353
8,793
8,089
7,999
6,276
7,472
11,689
11,523
12,409
11,988
12,202
12,080
12,093
Return on Invested Capital (%)
3.82
3.78
5.13
3.04
- -
4.6
8.28
6.53
- -
3.95
- -
3.8
2.25
- -
Return on Capital (%)
3.97
4.2
6.16
4.07
- -
6.39
10.21
7.8
- -
5.23
- -
4.75
2.71
- -
Return on Common Equity (%)
3.98
4.16
6.83
4.76
2.5
8.53
15.76
10.83
2.1
6.13
-6.47
5.38
2.89
1.57

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
3,195
2,835
2,969
LT Borrowings
29
27
27
LT Finance Leases
35
32
31
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3,908
3,908
3,908
Market Capitalization
16,713
13,626
13,541

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
9,580
9,233
9,837
Cash, Cash Equivalents & STI
3,505
3,438
4,270
Accounts Receivable, Net
1,365
1,239
1,234
Inventories
4,183
3,923
3,664
Total Current Liabilities
4,455
3,996
4,200
Payables & Accruals
- -
- -
- -
ST Debt
3,195
2,835
2,969
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.85%
0.73%
-1%
Free Cash Flow
339.69%
-816.04%
-20.06%
Net Income, GAAP
-11.6%
-62.12%
-45.96%
Sales/Revenue/Turnover
11.37%
1.73%
3.75%
Total Cash Common Dividend
22%
25.93%
169.42%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,373
1,464
1,232
1,212
5,281
2025
1,394
1,423
- -
1,285
5,479
2026
1,331
1,249
1,217
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.35
0.08
-0.09
0.17
2025
0.04
0.18
- -
-0.14
0.09
2026
0.05
0.06
0.08
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.02
0.03
0.02
0.04
2025
0.01
0.02
- -
0.01
0.11
2026
- -
0.15
0.01
- -
- -

Company Description

CEO
Yu Shan
Full Time Employees
2,150
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 21 Langshan Road Shenzhen GD China 518057
IPO Date
May 6, 2010
Business
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily focused on heparin and its derivatives. Its core offerings include finished dose pharmaceutical products such as enoxaparin sodium injections, prolongin, inhixa, neoparin, and heparin; active pharmaceutical ingredients (APIs) including heparin sodium API, enoxaparin sodium API, and pancreatin API; as well as molecule biologics contract development and manufacturing organization (CDMO) services encompassing research and development, manufacturing, quality management, program management, and technical support. The company also develops innovative drug candidates including apabetalone (RVX-208), a BET bromodomain protein inhibitor in clinical trials for cardiovascular and metabolic diseases, and monoclonal antibodies such as oregovomab. Founded in 1998 and headquartered in Shenzhen, China, Hepalink operates globally with a focus on markets in China, the United States, Europe, and emerging regions, exporting to over 80 countries. The company maintains a robust production capacity, particularly in enoxaparin sodium finished doses, which supports its leadership in the global anticoagulant market. Recent major developments include a strategic focus on international expansion, leveraging Europe as a regional hub and deepening market penetration in China and the U.S., accompanied by a sales growth of over 30% in finished dose pharmaceuticals for the most recent reporting period. Hepalink has enhanced its production capabilities with new formulation production lines to support internationalization initiatives and increase competitiveness. The company announced governance restructuring proposals in 2025, including the abolition of its Supervisory Committee and the election of an independent non-executive director to improve internal governance. Hepalink continues to invest heavily in research and development, dedicating over 10% of annual revenue toward innovation and recently launching new heparin formulations and biosimilar products. Its strategic partnerships include alliances with leading U.S.-based pharmaceutical firms to expand product offerings and enhance global reach. Hepalink’s operational improvements and cost control efforts have contributed to improved gross margins and operational efficiency. Shenzhen Hepalink’s business segments encompass finished dose pharmaceutical products, APIs, CDMO services, and biopharmaceutical research and production, catering to healthcare providers, pharmaceutical companies, and distributors globally. The company’s products primarily address anticoagulation therapies, particularly heparin and low molecular weight heparins (LMWH), with supplementary focus areas in oncology and orthopedics. It supports global healthcare through stringent quality control that meets international regulatory standards, holding certifications from multiple regulatory bodies. The company also promotes sustainability initiatives aimed at reducing carbon emissions and increasing energy efficiency within its manufacturing processes. Overall, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. stands as a leading global player in the heparin and anticoagulant market, backed by strong R&D capabilities, expansive global distribution, strategic governance updates, and ongoing commitment to innovation and quality manufacturing. It continues to expand its market footprint while enhancing product portfolios and operational excellence to maintain competitive advantage in the pharmaceutical industry.